Statistics from Altmetric.com
I read with interest the findings of an observational cohort study in which patients with AS receiving infliximab (IFX) (n=22) were compared for radiographic progression over 8 years with a historical cohort (n=34) naive to antitumour necrosis factor α therapy (anti-TNF).1 After adjusting for baseline damage there was no difference between treatment groups over the 0–4-year time frame, but a significantly greater rate of progression was evident in the 4–8-year time frame in the historical cohort. The authors then conclude that since there was less bone formation in the IFX-treated group, these data argue against a major role for the TNF-brake hypothesis.
The basis for this concluding statement is that the authors interpret the TNF brake hypothesis as implying that the use …
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.